

COMPUGEN LTD.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(U.S. dollars in thousands, except for share and per-share amounts)

	Three Months Ended		Six Months Ended	
	<u>June 30,</u>		<u>June 30,</u>	
	2010	2009	2010	2009
	<u>Unaudited</u>	<u>Unaudited</u>	<u>Unaudited</u>	<u>Unaudited</u>
Revenues	800	225	925	225
Cost of revenues	198	-	198	-
Research and development expenses	1,339	1,510	2,974	2,923
Less: governmental and other grants	(524)	(368)	(524)	(517)
Research and development expenses, net	815	1,142	2,450	2,406
Sales and marketing expenses	179	213	367	485
General and administrative expenses	545	409	1,565	988
Total operating expenses *	1,539	1,764	4,382	3,879
Operating loss	(937)	(1,539)	(3,655)	(3,654)
Financing income, net	41	279	40	36
Other income, net	-	3,619	-	3,681
Net income (loss) from continuing operations	(896)	2,359	(3,615)	63
Income from discontinued operations	-	5	-	-
Net income (loss)	(896)	2,364	(3,615)	63
Basic and diluted net earnings (loss) per ordinary share	(0.03)	0.08	(0.11)	0.01
Weighted average number of ordinary shares used in computing basic net earnings (loss) per share	33,272,718	28,512,440	33,142,182	28,512,440
Weighted average number of ordinary shares used in computing diluted net earnings (loss) per share	33,272,718	28,754,207	33,142,182	28,746,311

\* Includes stock based compensation

COMPUGEN LTD.  
CONDENSED CONSOLIDATED BALANCE SHEET DATA  
(U.S. dollars, in thousands)

	<b>June 30, 2010 Unaudited</b>	<b>December 31, 2009 Audited</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents and short-term bank deposits	21,052	15,639
Restricted cash	143	161
Trade receivables	250	-
Receivables and prepaid expenses	1,813	720
Receivables on account of shares	-	7,790
<b>Total current assets</b>	<b>23,258</b>	<b>24,310</b>
<b>Long-term investments</b>		
Investment in Evogene	3,784	3,898
Long-term lease deposits	18	18
Severance pay fund	1,253	1,224
<b>Total long-term investments</b>	<b>5,055</b>	<b>5,140</b>
<b>Property and equipment, net</b>	<b>641</b>	<b>735</b>
<b>Total assets</b>	<b>28,954</b>	<b>30,185</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable and accrued expenses	1,082	1,357
Deferred revenues	69	113
<b>Total current liabilities</b>	<b>1,151</b>	<b>1,470</b>
<b>Accrued severance pay</b>	<b>1,468</b>	<b>1,317</b>
<b>Total shareholders' equity</b>	<b>26,335</b>	<b>27,398</b>
<b>Total liabilities and shareholders' equity</b>	<b>28,954</b>	<b>30,185</b>